Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7244646 | 0.84 | NPC1 (0.49) | L3MBTL1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL30945299 | 0.80 | L3MBTL1 (0.69) | L3MBTL1 | |
| SCHEMBL8300753 | 0.80 | L3MBTL1 (0.69) | L3MBTL1NPSR1 | |
| SCHEMBL21621418 | 0.79 | L3MBTL1 (0.67) | L3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL6629239 | 0.78 | L3MBTL1 (0.73) | L3MBTL1 | |
| SCHEMBL12643699 | 0.77 | L3MBTL1 (0.64) | L3MBTL1ALDH1A1 | |
| SCHEMBL13823926 | 0.77 | L3MBTL1 (0.72) | L3MBTL1 | |
| SCHEMBL8899583 | 0.77 | L3MBTL1 (0.76) | L3MBTL1 | |
| SCHEMBL5713023 | 0.76 | L3MBTL1 (0.63) | L3MBTL1NPSR1 | |
| SCHEMBL9781776 | 0.76 | L3MBTL1 (0.78) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030009030-A1 | Novel selective deacetylating agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-09 | — | — | US | disclosed |
| EP-1245550-A1 | NOVEL SELECTIVE DEACETYLATING AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030009030-A1 | Novel selective deacetylating agents | HDAC1, HDAC11, HDAC3 | L3MBTL1 2745/4885NPC1 877/4885RAB9A 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.